Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.

Prostate Cancer Prostatic Dis · 2026 · PMC13139911 · PMID 41820670

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

a strong trendp = 0.053so close (0.05 < p ≤ 0.1)

After multivariate adjustment, total SM concentration remained significantly associated with OS (HR = 0.49, 95% CI = 0.24–0.97, p = 0.04), while showing a strong trend towards statistical significance for PFS (HR = 0.49, 95% CI = 0.31–1.01, p = 0.053; Supplementary Fig. 3 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.